Asia
Mabpharm's Application for Osteoporosis Drug Approved in China
Mabpharm's (HKG:2181) new drug application of CMAB807 (denosumab injection) has been approved by China's National Medical Products Administration, according to a Tuesday Hong Kong bourse filing.The approval is for use of the drug to treat osteoporosis in postmenopausal women and men at increased risk of fracture, as well as glucocorticoid-induced osteoporosis.
HKG:2181
